AstraZeneca Datroway therapy wins key EU backing, shares follow Jefferies Buy call

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 13:10.

AstraZeneca (GB0009895292) enters the new week with a fresh regulatory milestone in Europe. Datroway, developed with Daiichi Sankyo, has received a positive recommendation for EU approval as a first-line treatment for metastatic triple negative breast cancer, which adds a new potential growth pillar for the London-listed FTSE 100 constituent according to recent coverage by Reuters and MarketScreener.

Regulators back Datroway in Europe

Daiichi Sankyo and AstraZeneca announced that an EMA advisory committee has recommended Datroway for approval in the European Union as a first-line therapy for patients with metastatic triple negative breast cancer who are not candidates for immunotherapy, marking a significant expansion of the drug's commercial opportunity in oncology per the joint statement cited by MarketScreener. The recommendation positions Datroway as an option for a hard-to-treat tumor type where existing therapies are limited and prognosis remains poor, and it reflects the partners' broader strategy to build out antibody-drug conjugates in multiple indications, a portfolio segment that has been a key focus of AstraZeneca's R&D spend in recent years.

Jefferies keeps AstraZeneca at Buy

Alongside the Datroway news, Jefferies reiterated its Buy rating on AstraZeneca shares with a price target of 18,000 pence, underlining the broker's positive stance on the company's earnings and pipeline outlook, as reported by MarketScreener in its June 26 analyst summary. The Jefferies note highlights AstraZeneca's diversified portfolio across oncology, cardiovascular, renal and metabolic diseases and respiratory indications, and points to Datroway's EU progress as a supportive datapoint for medium-term revenue growth, while also flagging currency and pricing dynamics as factors investors must monitor in the London Stock Exchange-listed stock.

What the company sells

AstraZeneca generates most of its revenue from prescription medicines across oncology, cardiovascular, renal and metabolic diseases, and respiratory and immunology, with key brands such as Tagrisso in lung cancer and Farxiga in diabetes and heart failure featuring prominently in recent annual reports and product portfolios on its Investor Relations site. The company also invests heavily in biologics and antibody-drug conjugates, an area where Datroway exemplifies the strategy of combining targeted delivery with cytotoxic agents to improve outcomes in aggressive cancers.

Where the stock trades today

The AstraZeneca shares (GB0009895292) last closed on June 26, 2026 on the NYSE at 188.58 US dollars, with post-market trading at 188.18 dollars according to MarketBeat’s price data.

This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell securities. All data were obtained from sources considered reliable but cannot be guaranteed; investors should conduct their own research or consult a qualified advisor before making investment decisions.